EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

被引：0

作者：

Noh, H. ^{[1
]}

Choi, S. -Y. ^{[2
]}

Song, H. -Y. ^{[2
]}

Kim, S. -H. ^{[2
]}

Jung, S. Y. ^{[3
,4
]}

Yang, S. ^{[1
]}

Lee, W. -S. ^{[5
]}

Kim, H. -J. ^{[6
]}

Kong, J. H. ^{[7
]}

Kim, H. ^{[8
]}

Do, Y. R. ^{[9
]}

Kwak, J. -Y. ^{[10
]}

Oh, S. ^{[11
]}

Kim, S. H. ^{[12
]}

Kim, J. -A. ^{[13
]}

Zang, D. Y. ^{[14
]}

Mun, Y. -C. ^{[15
]}

Won, Y. -W. ^{[16
]}

Lee, S. -E. ^{[17
]}

Kim, D. -W. ^{[17
]}

Lee, J. ^{[3
,4
]}

机构：

[1] Yonsei Univ, Dept Pharm, Coll Pharm, Incheon, South Korea

[2] Catholic Univ Korea, Leukemia Res Inst, Seoul, South Korea

[3] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul, South Korea

[4] Seoul Natl Univ, Coll Pharm, Dept Pharm, Seoul, South Korea

[5] Inje Univ, Busan Paik Hosp, Coll Med, Dept Internal Med, Busan, South Korea

[6] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Hwasun, South Korea

[7] Yonsei Univ, Wonju Coll Med, Dept Hematol Oncol, Wonju, South Korea

[8] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Hematol, Ulsan, South Korea

[9] Keimyung Univ, Keimyung Univ Hosp, Sch Med, Div Hematol Oncol, Daegu, South Korea

[10] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Sch Med, Div Hematol Oncol, Jeonju, South Korea

[11] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Internal Med,Div Hematol Onco, Seoul, South Korea

[12] Dong A Univ, Dong A Univ Hosp, Coll Med, Dept Internal Med, Busan, South Korea

[13] Catholic Univ Korea, St Vincents Hosp, Dept Hematol, Suwon, South Korea

[14] Hallym Univ, Hallym Univ Hosp, Coll Med, Dept Internal Med, Anyang, South Korea

[15] Ewha Womans Univ, Ehwa Womans Univ Hosp, Sch Med, Dept Hematol, Seoul, South Korea

[16] Hanyang Univ, Guri Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Guri, South Korea

[17] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Dept Hematol, Seoul, South Korea

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P259

引用

页码：76 / 76

页数：1

共 50 条

[31] GENETIC MUTATIONS OUTSIDE BCR-ABL1 DETERMINING TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA
Aref, Salah
Abdalla, Nada
Muller, Martin
El Sharaway, Solofa
Aziz, Sherin Abdel
Sauselle, Sussane
[J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 : 17 - 17
[32] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
Hyewon Lee
Igor Novitzky Basso
Dennis Dong Hwan Kim
[J]. International Journal of Hematology, 2021, 113 : 632 - 641
[33] BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Amarante-Mendes, Gustavo P.
Rana, Aamir
Datoguia, Tarcila Santos
Hamerschlak, Nelson
Brumatti, Gabriela
[J]. PHARMACEUTICS, 2022, 14 (01)
[34] Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Katalinic, D.
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S100 - S100
[35] Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study
Iino, Masaki
[J]. ANNALS OF ONCOLOGY, 2017, 28
[36] Immunological and Molecular Investigation of BCR-ABL1 in Samples of Iraqi Chronic Myeloid Leukemia Patients
Mohammad, Farooq I.
Nadim, Alaa R.
[J]. JOURNAL OF PIONEERING MEDICAL SCIENCES, 2024, 13 (01): : 94 - 98
[37] Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Fominykh, Mikhail
Shuvaev, Vasily
Martynkevich, Irina
Shukhov, Oleg
Chelysheva, Ekaterina
Turkina, Anna G.
Abdulkadyrov, Kudrat
[J]. BLOOD, 2016, 128 (22)
[38] Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
Langabeer, Stephen E.
McCarron, Sarah L.
Haslam, Karl
Preston, Lisa
[J]. CLINICAL LABORATORY, 2016, 62 (05) : 975 - 976
[39] Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes
Stuckey, Ruth
Casado, Luis-Felipe
Colomer, Dolors
Teresa Gomez-Casares, Maria
Casas, Laura
Garcia-Gutierrez, Valentin
Luis Sastre, Jose
Ramirez-Payer, Angel
Vall-Llovera, Ferran
Angeles Goni, Maria
Xicoy, Blanca
Cristina Godoy, Ana
Nunez, Javier
Mora, Itxaso
Vallansot, Rolando
Luis Lopez-Lorenzo, Jose
Palomera, Luis
Conesa, Venancio
Soledad Noya, Maria
Sanchez-Guijo, Fermin
Pena, Ascension
Bautista, Guiomar
Luis Steegmann, Juan
[J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (10): : 1217 - 1224
[40] Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors
Lin, Jay
Dinara, Makenbaeva
Robyn, Bilmes
Lingohr-Smith, Melissa
Wallis, Nicola
[J]. BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →